Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Filling in the Gaps in AAA Repair

This article was originally published in Start Up

Executive Summary

The first stent grafts created a market for the endovascular repair of abdominal aortic aneurysms. They also created new problems for start-ups to overcome. New companies have risen to the problem of avoiding endoleaks, with new stent graft designs and attachment systems, and also solutions for continuous monitoring.

You may also be interested in...



In Search of the Perfect Aortic Endograft

The aortic endograft market stands out in the medical device arena for its rich history of failure. The number of products that have been pulled from the market or axed before they reached it exceeds the number of models currently available in the US. But despite these past failures, endovascular aortic procedures have thrived thanks to researchers’ tenacity. At this year's International Congress on Endovascular Interventions, top surgeons discussed a number of new devices and techniques aimed at widening the scope of endovascular aortic repair to a broader range of patients.

Medical Metrx Solutions Inc.

Medical Metrx Solutions, which can derive precise measurements from three-dimensional images of a patient's anatomy, aims to solve the three S's of abdominal aortic aneurysms: selection, sizing and surveillance.

EVA Corp.

In AAA repair, EVA believes that its endostaple, which can provide secure attachment of an endograft under dynamic conditions, will go a long way towards solving some of the problems that plague existing stent grafts.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel